Home / Stocks / Mangalam Drug & Chem Ltd
MANGALAM

Mangalam Drug & Chem Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹28.56

Change

+0.17 (0.6%)

Open

₹28.39

Prev. Close

₹28.39

Day High

₹28.98

Day Low

₹28.03

Volume Analysis

Traded

2,660

Delivered

1,693

Delivery %

63.65%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (5)

  • •High debt-to-equity ratio (1.02)
  • •Low return on equity (-35.3%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (27/100)
  • •Low operating margin (-2.8%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹29.96 ₹29.47 ₹29.01 ₹28.52 ₹28.06 ₹27.57 ₹27.11
Fibonacci ₹29.47 ₹29.11 ₹28.88 ₹28.52 ₹28.16 ₹27.93 ₹27.57
Camarilla ₹28.82 ₹28.73 ₹28.65 ₹28.52 ₹28.47 ₹28.39 ₹28.3

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-1.11%

1 Week

-2.12%

1 Month

-6.11%

3 Months

+3.18%

6 Months

-2.89%

1 Year

-40.91%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹31.64

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

-35.59%

Net margin -14.5% × asset turnover 1.04x × equity multiplier 2.36x

Company Overview

Sector

Healthcare

Market Cap

₹45 Cr

ROE

-35.3%

Book Value

₹55.6

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Mangalam Drug & Chem Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 27/100. The strongest factor is Financial Strength (58/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (1.02); low return on equity (-35.3%).

TopFund Score — Fundamentals Quality

27/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

58

Growth

0

Valuation

38

Cash Flow

2

Corporate Governance

36

Momentum

17

Institutional Ownership

30

Business Quality

18

Risk & Volatility

37

Liquidity

43

From Screener.in

  • +Stock is trading at 0.51 times its book value
  • −Company has low interest coverage ratio.
  • −Promoter holding is low: 35.6%
  • −Company has a low return on equity of -11.6% over last 3 years.
  • −Debtor days have increased from 45.3 to 63.4 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Board approved exploring sale of Unit-2 Vapi land and building; EGM planned for FY2026-27 approval.

Company disclosed default on Bank of Maharashtra and Bank of Baroda loans; overdue totals Rs 1,557.27 lakh.

Defaulted on Bank of Maharashtra (₹951.19 lakh, 17 Oct 2025) and Bank of Baroda (₹606.08 lakh, 20 Oct 2025).

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 82 97 102 77 80 89 73 57 50 58 67 57 79
Expenses + 79 90 91 68 71 80 63 62 52 60 73 56 81
Operating Profit 2 7 12 8 9 9 10 -5 -3 -2 -6 1 -1
OPM % 2.69% 7.17% 11.43% 10.7% 10.88% 9.89% 13.6% -8.08% -5.73% -2.64% -8.35% 1.59% -1.45%
Other Income + 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 3 3 4 4 4 3 4 4 5 4 3 4 4
Depreciation 4 4 4 4 4 4 5 4 5 4 5 4 4
Profit before tax -5 0 4 1 1 1 2 -13 -12 -10 -13 -7 -9
Tax % -25.05% -1,150.0% 10.18% -362.07% -124.17% 5.84% 95.73% 6.15% -41.06% 0.0% 1.13% 13.19% -19.8%
Net Profit + -4 1 4 3 3 1 0 -14 -7 -10 -13 -8 -7
EPS in Rs -2 0 2 2 2 1 0 -9 -5 -6 -8 -5 -5
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -25 — — — — -9 -29 -25 -38 -34 -8 0 60

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 221 295 299 269 228 282 380 451 372 369 318 232 262
Expenses + 200 257 252 222 218 259 327 402 347 351 282 247 270
Operating Profit 20 38 47 47 10 24 53 49 26 17 36 -15 -7
OPM % 9.0% 13.0% 16.0% 17.0% 4.3% 8.0% 14.0% 11.0% 7.0% 4.7% 11.0% -6.0% -2.8%
Other Income + 0 0 0 1 0 1 5 0 0 0 1 1 1
Interest 10 9 10 12 9 10 9 11 13 14 15 16 15
Depreciation 4 4 5 7 7 8 9 10 11 15 17 18 17
Profit before tax 6 24 31 29 -6 6 40 28 2 -11 5 -49 -39
Tax % -2.0% 33.0% 29.0% 32.0% 40.0% -32.0% 29.0% 29.0% 43.0% -18.0% -41.0% -9.0% —
Net Profit + 6 16 22 20 -8 8 28 20 1 -9 7 -44 -38
EPS in Rs 5 11 14 13 -5 5 18 12 1 -6 4 -28 -24
Dividend Payout % 0.0% 0.0% 0.0% 4.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth 80 34 1 -10 -15 24 35 19 -17 — -14 -27 -2

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 16 47 70 88 80 88 115 135 136 120 133 87 72
Borrowings + 78 60 66 69 65 52 70 88 89 107 96 113 90
Other Liabilities + 63 38 38 54 50 75 64 90 117 91 121 99 120
Total Liabilities 170 160 190 227 211 231 264 328 358 334 366 315 298
Fixed Assets + 53 54 93 102 103 101 118 135 142 148 163 155 152
CWIP 0 5 0 0 0 1 6 6 9 8 3 4 0
Investments 0 0 2 0 0 0 0 0 0 0 0 0 0
Other Assets + 117 100 95 125 107 128 140 188 206 178 201 156 146
Total Assets 170 160 190 227 211 231 264 328 358 334 366 315 298
Equity Capital 13 14 16 16 16 16 16 16 16 16 16 16 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 14 22 43 25 22 31 28 26 38 4 43 4
Cash from Investing Activity + -4 -11 -39 -16 -9 -7 -31 -27 -22 -12 -19 -12
Cash from Financing Activity + -10 -11 -3 -9 -11 -23 3 3 -17 5 -22 6
Net Cash Flow 1 0 0 0 1 0 -1 1 -1 -3 1 -2
Free Cash Flow 10 11 3 9 12 24 -4 -2 16 -8 23 -8
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 69 68 107 66 223 129 69 70 148 23 120 -30

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 50.31% → 35.65%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 49.59% 49.42% 49.47% 49.58% 49.58% 49.23% 49.16% 49.57% 64.22% 64.03% 64.24% 64.24%
Promoters 50.31% 50.31% 50.31% 50.3% 50.3% 50.3% 50.3% 50.3% 35.64% 35.65% 35.65% 35.65%
FII 0.1% 0.26% 0.21% 0.11% 0.11% 0.47% 0.53% 0.11% 0.13% 0.32% 0.11% 0.11%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Mangalam Drug & Chem Ltd (this stock) 45 — 0.51 -35.3%
Vivimed Labs Limited 43 — -0.2 —
Vivo Bio Tech Ltd. 35 — 0.37 -2.24%
Medi Caps Ltd. 33 — 0.27 -9.21%
Gkb Ophthalmics Ltd. 31 11.2 0.56 3.28%
Sunil Healthcare Ltd. 78 26.6 1.03 6.01%
Ortin Global Limited 11 — — —

Which Mutual Funds Hold Mangalam Drug & Chem Ltd?

Frequently Asked Questions about Mangalam Drug & Chem Ltd

Community Sentiment

What are other investors saying about Mangalam Drug & Chem Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.